GV101

DRUG2 trials

Sponsors

Graviton Bioscience Corporation

Conditions

Phase 1Weight Management

Phase 1

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

CompletedNCT05068947

Graviton Bioscience CorporationPhase 1

Start: 2021-09-10End: 2021-10-22Updated: 2023-10-17

Phase 2

GV101 in Healthy Obese Participants

CompletedNCT06979505

Graviton Bioscience CorporationWeight Management

Start: 2025-06-30End: 2026-01-28Updated: 2026-02-04